Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 6, 2025
Reporting Period: Event-based report regarding a program update presented on December 6, 2025.
Key Financial Metrics
This filing is an event-based report (Item 8.01) and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the presentation of an update on the Company's enozertinib (ORIC-114) program. This update included recently announced data from the Company's Phase 1b trial of enozertinib. No financial material changes were reported in this document.
Guidance, Outlook, and Management Commentary
Management Commentary: The Company presented data from the Phase 1b trial of enozertinib. A detailed presentation containing this data is attached as Exhibit 99.1 and incorporated by reference.
Guidance and Risks: This specific filing does not contain updated financial guidance, risk factors, or contingencies beyond the standard disclosure of the clinical trial update.
Investor Verification Checklist
- Review Exhibit 99.1 (Presentation) for specific clinical data points from the enozertinib Phase 1b trial.
- Verify the clinical significance of the Phase 1b data in the context of the drug's development timeline.
- Check subsequent filings for any financial impact or strategic shifts resulting from the trial data.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing).